- Home
- IOBT
IOBT
IO Biotech Inc.
as 03-25-2025 4:00pm EST
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
| Founded: | 2014 | Country: | Denmark |
| Employees: | N/A | City: | COPENHAGEN |
| Market Cap: | 57.9M | IPO Year: | 2021 |
| Target Price: | $9.33 | AVG Volume (30 days): | 191.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $1.84 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest IO Biotech Inc. News
IOBT Breaking Stock News: Dive into IOBT Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025
GlobeNewswire
22 days ago
IO Biotech Reports 2024 Business Highlights
GlobeNewswire
a month ago
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
GlobeNewswire
a month ago
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
GlobeNewswire
2 months ago
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
Clinical Trials Arena
3 months ago
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy
MT Newswires
3 months ago
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
GlobeNewswire
3 months ago
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
Compare IOBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOBT IO Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.